Work in the laboratory of Arun Sharma, PhD, focuses on applying human induced pluripotent stem cells (hiPSCs) to model cardiovascular diseases in vitro. The lab utilizes cutting-edge technologies, including hiPSCs, CRISPR/Cas9 genome editing, cardiac microfluidic organ-chips and cardiac organoids in our studies. Specifically, we have used hiPSC-derived cardiomyocytes (heart muscle cells) to model cardiac viral infections during COVID-19, examine developmental mechanisms underlying congenital heart disease and understand ways to alleviate cardiac toxicity caused by cancer drugs. In our ongoing studies, we have a unique background and interest in space biology, notably exploring ways in which stem cell biology can intersect with this emerging field.
I have a long-standing interest in the intersection of stem cell biology and cardiovascular biology, focusing on effectively modeling diseases in a dish. I am particularly excited about making in vitro biology as close as possible to in vivo. Recent technological developments, like CRISPR/Cas9 and organ-chips, can elevate in vitro disease modeling. Beyond the lab, I advocate for effectively communicating science to general and scientific audiences through public speaking, while mentoring junior scientists at Cedars-Sinai and beyond."
- Using stem cell-derived cardiovascular cells to model chemotherapy-induced cardiovascular toxicity.
- Developing multicell lineage in vitro platforms, such as cardiovascular organ-chips and cardiac organoids, for studying cardiovascular diseases in a dish.
- Studying the effects of microgravity and spaceflight on human tissues using stem cell-derived cells as a model and for biomanufacturing purposes.
The Sharma Lab collaborates with a wide range of investigators within Cedars-Sinai and institutions around the world.